The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: Muscarinic receptor binding and pharmacokinetics

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1314-1321

  Yamada, Shizuo ^a   Ito, Yoshihiko ^a   Taki, Yuko ^a   Seki, Masanao ^a   Nanri, Masato ^b   Yamashita, Fumiaki ^b   Morishita, Kayo ^b   Komoto, Ikumi ^b   Yoshida, Ken Ichiro ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PIPERIDYL BENZILATE N OXIDE; 1 METHYL 4 PIPERIDYL DIPHENYLPROPOXYACETATE N OXIDE; DRUG METABOLITE; MUSCARINIC RECEPTOR; PROPIVERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBMANDIBULAR GLAND;

ANIMALS; BENZILATES; CHOLINERGIC ANTAGONISTS; PROTEIN BINDING; RATS; RECEPTORS, MUSCARINIC; SUBMANDIBULAR GLAND; URINARY BLADDER;

RATTUS;

EID: 77954942825     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033233     Document Type: Article

References (34)

1. Alloussi S, Baldauf J, Derouet H, Zwergel U, and Meessen S (1991) Effect of trospium chloride, oxybutynin and propiverine on the interaction of acetylcholine with isolated preparations of the human urinary bladder, in Investigative Urology, 4th ed (Jocham D, Thuroff JW, and Rudden H eds) pp 157-161, Springer-Verlag, New York.
2. Andersson KE (1993) Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45:253-308.
3. Bulmer P and Abrams P (2000) The overactive bladder. Rev Contemp Pharmacother 11:1-11.
4. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:33-46.
5. Cyong JC, Uebaba K, Nishimura T, Takebe M, Takayanagi H, Yamamoto Y, Nagamachi M, Kawaguchi Y, Umeno Y, Shindo K, et al. (2006) Plasma pharmacokinetics and urinary excretion of propiverine hydrochloride in elderly population. Jpn Pharmacol Ther 34:869-875.
6. Halaska M, Dorschner W, and Frank M (1994) Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourol Urodynam 13:428-430.
7. Haruno A, Yamasaki Y, Miyoshi K, Miyake H, Tsuchiya K, Kosaka M, Nagai M, and Iriki M (1989) Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder. Nippon Yakurigaku Zasshi 94:145-150. (Pubitemid 19196055)
8. Haustein KO and Hüller G (1988) On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet 13:81-90.
9. Hüller G, Haustein KO, and Scheithauer S (1988) Studies on the metabolic pattern of propiverine in urine after single administration. Pharmazie 43:91-95. (Pubitemid 18061459)
10. Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, et al. (2009) Demonstration of bladder muscarinic M3 receptor selectivity of oral solifenacin in muscarinic receptor knockout mice. Eur J Pharmacol 615:201-206.
11. Kaneko S, Haruno A, Suzuki N, Kitazato K, Yamazaki Y, Nagai M, Iriki M, Tsuchiya K, and Kosaka M (1989) Effect of propiverine hydrochloride on the function of the bladder in dogs. Nippon Yakurigaku Zasshi 93:55-60.
12. Kaneko S, Nakano D, Ohara M, and Nishimori T (1999) Effects of propiverine hydrochloride (propiverine) on isolated rat and dog urinary bladder. Nippon Yakurigaku Zasshi 113:145-156.
13. Komoto I, Yoshida K, Matsushima E, Yamashita K, Aikawa T, and Akashi S (2004) Validation of a simple liquid chromatography-tandem mass spectrometric method for the determination of propiverine hydrochloride and its N-oxide metabolite in human plasma. J Chromatogr B Analyt Technol Diomed Life Sci 799:141-147.
14. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 93:265-275.
15. Madersbacher H, Halaska M, Voigt R, Alloussi S, and Höfner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646-651.
16. Madersbacher H and Mürtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19:324-335. (Pubitemid 33777078)
17. Meisel P, Langner S, and Siegmund W (1997) In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. J Pharm Pharmacol 49:270-272. (Pubitemid 27197011)
18. Nomura N, Kaneko S, Hamakawa T, Nagai M, and Iriki M (1989) Effects of propiverine hydrochloride (P-4) and its metabolites on urinary bladder function in anesthetized rats. Nippon Yakurigaku Zasshi 94:173-180. (Pubitemid 19217497)
19. Oki T, Kimura R, Saito M, Miyagawa I, and Yamada S (2004) Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol 172:2059-2064.
20. Oki T, Yamada S, Tohma A, and Kimura R (2001) Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine. Biol Pharm Bull 24:491-495.
21. Resnick NM and Yalla SV (1985) Management of urinary incontinence in the elderly. N Engl J Med 313:800-805.
22. Riotte J and Mutschler E (1987) The spasmolytic activity of propiverine and some of its structural analogs. Arzneimittelforschung 37:300-302.
23. Stöhrer M, Madersbacher H, Richter R, Wehnert J, and Dreikorn K (1999) Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia-a double-blind, placebocontrolled clinical trial. Spinal Cord 37:196-200.
24. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sörgel F, Klaassen T, Kasel D, Harlfinger S, Doroshyenko O, Frank D, et al. (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33:1859-1866.
25. Tsuda M, Yamamoto Y, Uda K, Shindo T, and Kawaguchi Y (1991) Pharmacokinetic studies of propiverine hydrochloride(5): animal differences in vivo, in vitro and protein binding. Xenobiotic Metab Dispos 6:3-20.
26. Wada Y, Yoshida M, Kitani K, Kikukawa H, Ichinose A, Takahashi W, Gotoh S, Inadome A, Machida J, and Ueda S (1995) Comparison of the effects of various anticholinergic drugs on human isolated urinary bladder. Arch Int Pharmacodyn Ther 330:76-89.
27. Wengler A, Schneider T, Zschiesche M, and Siegmund W (1988) Studies on the metabolism of the bladder spasmolytic, propiverine (mictonorm) in humans. Pharmazie 43:652-653.
28. Wuest M, Hecht J, Christ T, Braeter M, Schoeberl C, Hakenberg OW, Wirth MP, and Ravens U (2005) Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 145:608-619. (Pubitemid 41032633)
29. Wuest M, Weiss A, Waelbroeck M, Braeter M, Kelly LU, Hakenberg OW, and Ravens U (2006) Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 374:87-97.
30. Yamada S, Isogai M, Kagawa Y, Takayanagi N, Hayashi E, Tsuji K, and Kosuge T (1985) Brain nicotinic acetylcholine receptors. Biochemical characterization by neosurugatoxin. Mol Pharmacol 28:120-127.
31. Yamada S, Kusaka T, Urayama A, Kimura R, and Watanabe Y (2003) In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N/OFQ and [35S]GTPγS in rat brain and spinal cord. Br J Pharmacol 139:1462-1468.
32. 3H]WB4101: effect of 6-hydroxydomine treatment. J Pharmacol Exp Ther 215:176-185.
33. Yamamoto Y, Tsuda M, Uda K, Matsushita H, Shindo T, and Kawaguchi Y (1995) Pharmacokinetic studies on propiverine hydrochloride-metabolites in urinary bladder, other tissues, and urine of rats. Xenobiotic Metab Dispos 10:205-210.
34. Yamamoto Y, Tsuda M, Uda K, Shindo T, and Kawaguchi Y (1989) Pharmacokinetic studies of propiverine hydrochloride (1) absorption, distribution, and excretion after a single administration to rats. Xenobiotic Metab Dispos 4:537-551.